BIOR - Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium | Benzinga
SAN DIEGO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will participate in the Inflammatory Bowel Disease Symposium hosted virtually by Canaccord Genuity Capital Markets on Wednesday, February 28, 2024.
Ariella Kelman, M.D., Chief Medical Officer, will participate in the panel titled "The Next Evolutionary Steps in Addressing IBD," beginning at 10:00 AM Eastern / 7:00 AM Pacific time.
Interested parties may contact their Canaccord Genuity representative to request registration details for the virtual event.
About Biora Therapeutics
Biora Therapeutics is reimagining therapeutic delivery. By creating innovative smart pills designed for targeted drug delivery to the GI tract, and systemic, needle-free delivery of biotherapeutics, the company is developing therapies to improve patients' lives.
Biora is focused on development of two therapeutics platforms: the clinical-stage NaviCap™ targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract, and the preclinical-stage BioJet™ systemic oral ...